Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI.

[1]  Mário João Fartaria,et al.  Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity , 2020, Scientific Reports.

[2]  J. Rinne,et al.  Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[3]  L. Airas,et al.  Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity , 2020, Multiple sclerosis.

[4]  R. Henry,et al.  Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. , 2019, JAMA neurology.

[5]  C. Vedeler,et al.  Neurofilament Light Chain as a Biomarker in Multiple Sclerosis , 2019, Front. Neurol..

[6]  J. Kassubek,et al.  Serum GFAP as a biomarker for disease severity in multiple sclerosis , 2018, Scientific Reports.

[7]  Ludwig Kappos,et al.  Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.

[8]  D. Pitt,et al.  The Role of Astrocytes in Multiple Sclerosis , 2018, Front. Immunol..

[9]  S Ekholm,et al.  Diffusion tensor imaging in multiple sclerosis at different final outcomes , 2018, Acta neurologica Scandinavica.

[10]  Laura E. Danielian,et al.  Pathology of callosal damage in ALS: An ex-vivo, 7 T diffusion tensor MRI study , 2017, NeuroImage: Clinical.

[11]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[12]  Kevin K. W. Wang,et al.  Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker , 2015, Trends in Neurosciences.

[13]  A. Petzold.  Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease , 2015, Brain Research.

[14]  K. Blennow,et al.  Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis , 2015, Multiple sclerosis.

[15]  H. Zetterberg,et al.  Assessing tissue damage in multiple sclerosis: a biomarker approach , 2014, Acta neurologica Scandinavica.

[16]  P. Pantano,et al.  DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications , 2013, Multiple sclerosis international.